Combination pharmacotherapy in alcoholism: A novel treatment approach

CNS Spectrums

Volumn 5, Issue 2, 2000, Pages 70-76

  Farren, Conor K ^a,c   Rezvani, Amir H ^a,c   Overstreet, David ^a,b   O'Malley, Stephanie ^a,d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ACAMPROSATE; ALCOHOL; DISULFIRAM; DOPAMINE RECEPTOR; FLUOXETINE; ISRADIPINE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NALMEFENE; NALTREXONE; ONDANSETRON; OPIATE RECEPTOR; SEROTONIN; SEROTONIN ANTAGONIST; SEROTONIN RECEPTOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TALTIRELIN;

ABDOMINAL DISCOMFORT; ALCOHOL CONSUMPTION; ALCOHOLISM; ANXIETY; ARTHRALGIA; CLINICAL TRIAL; CONSTIPATION; DIARRHEA; DOPAMINERGIC SYSTEM; FATIGUE; FLUID INTAKE; GABAERGIC SYSTEM; HEADACHE; HUMAN; INSOMNIA; NAUSEA; NONHUMAN; PRIORITY JOURNAL; REVIEW; SEROTONINERGIC SYSTEM; SKIN TINGLING; TREMOR; VERTIGO;

EID: 0033951208     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900012839     Document Type: Review

References (43)

1. Stein G, Bemadt M. Lithium augmentation therapy in tricyclic-resistant depression: a controlled trial using lithium in low and normal doses. Br J Psychiatry. 1993;162:634640.
2. Zusky PM, Biederman, J, Rosenbaum JF, et al. Adjunct low dose lithium carbonate in treatment-resistant depression: a placebo-controlled study. J Clin 'Psychopharmacol. 1986;8:120-124.
3. Schöpf J, Baumann P, Lemarchand T, Rey M. Treatment of endogenous depressions resistant to tricyclic antidepressants or related drugs by lithium addition: results of a placebo-controlled double-blind study. Pharmacopsychialry. 1989;22:183-187.
4. Thase ME, Rush AJ. Treatment-resistant depression. In: Bloom FK, Kupfer DJ, eds. Psychopharmacology: The Fourth Generation of Progress. Baltimore, MD: Raven Press Ltd; 1995:1081-1097.
5. Ketter TA, Post RM, Parekh PI, Worthington K. Addition of monoamine oxidase inhibitors to carbamazepine: preliminary evidence of safety and antidepressant efficacy in treatment-resistant depression. J Clin Psychiatry. 1995;56:471-475.
6. Artigas F, Ferez V, Alvarez E. Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry. 1994;51:248-251.
7. Wolkowitz OM. Rational poly-pharmacy in schizophrenia. Ann Clin Psychiatry. 1993;5:79-90.
8. Kane J, Honigfeld G, Singer J, Meltzer H. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry. 1988;45:789-796.
9. Tollefson GD, Beasley CM Jr, Tran PV, et al. Olanzapine vs haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial. Am ] Psychiatry. 1997;lS4:457-465.
10. Fuller RK, Branchey L, Brightwell DR, et al. Disulfiram treatment of alcoholism: a Veterans Administration cooperative study. JAMA. 1986;256:1449-1455.
11. Swift R. Opioid antagonists and alcoholism treatment. CNS Spectrum. 2000;5(2):xx-xx.
12. Pettinati HJ, Oslin D, Decker K. Role of serotonin and serotonin-selective pharmacotherapy in alcohol dependence. CNS Spectrums. 2000;5(2):xx-xx.
13. Mason B. Acamprosate for the treatment of alcohol dependence: a review of double-blind, placebo-controlled trials. CNS Spectrums. 2000;5(2):xx-xx.
14. McBride WJ, Murphy JM, Lumeng L, Li T-K. Serotonin, dopamine and GABA involvement in alcohol drinking of selectively bred rats. Alcohol. 1990;7:199-205.
15. Sellers EM, Higgins GA, Sobell MB. 5-HT and alcohol abuse. Trends Pharmacol Sci. 1992;13:69-75.
16. Rezvani AH, Overstreet DH, Janowsky DS. Genetic serotonin deficiency and alcohol preference in the Fawn-Hooded rats. Alcohol Alcohol. 1990;25:573-575.
17. Rezvani AH, Grady DR. Suppression of alcohol consumption by fenfluramine in FawnHooded rats with serotonin dysfunction. Pharmacol Biochem Behav. 1994;48:105-110.
18. Koob GF, Rassnick S, Heinrichs S, Weiss F. Alcohol, the reward system and dependence. EXS. 1994;71:103-114.
19. Froehlich JC, Harts J, Lumeng L, Li T-K. Naloxone attenuates voluntary ethanol intake in rats selectively bred for high ethanol preference. Pharmacol Biochem Behav. 1990;35:385-390.
20. Reid LD. Endogenous opioids and alcohol dependence: opioid alkaloids and propensity to drink alcohol beverages. Alcohol. 1996;13:5-11.
21. Hjorth S, Westlin D, Bengtsson HJ. WAY100635-induced augmentation of the 5HT-elevating action of citalopram: relative importance of the dose of the 5-HTIA (auto) receptor blocker vs that of the 5-HT reuptake inhibitor. Neuropharmacology. 1997;36:461465.
22. Zhou FC, McKinzie DL, Patel TD, Lumeng L, Li T-K. Additive reduction of alcohol drinking by 5-HT1A antagonist WAY 100635 and serotonin uptake blocker fluoxetine in alcohol-preferring P rats. Alcohol Clin Exp Res. 1998;22:266-269.
23. Le AD, Sellers EM. Interaction between opiate and 5-HTj receptor antagonists in the regulation of alcohol intake. Alcohol Alcohol Suppl. 1994;2:545-549.
24. Benjamin D, Grant ER, Pohorecky LA. Naltrexone reverses ethanol-induced dopamine release in the nucleus accumbens in awake, freely moving rats. Brain Res. 1993;621:137-140.
25. Wozniak KM, Pert A, Linnoila M. Antagonism of 5-HT3 receptors attenuates the effects of ethanol on extracellular dopamine. Eur J Pharmacol. 1990;187:287-289.
26. 26.0'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. Arch Gtn Psychiatry. 1992;49:475-481.
27. Sellers EM, Toneatto T, Romach MK, Somer GR, Sobell L, Sobell MB. Clinical efficacy of the 5-HT3 antagonist ondansetron in alcohol abuse and dependence. Alcohol Clin Exp Res. 1994;18:879-885.
28. Rezvani AH, Pucilowski 0, Grady DR, Janowsky D, O'Brien RA. Reduction of spontaneous alcohol drinking and physical withdrawal by levemopamil, a novel Ca channel antagonist, in rats. Pharmacol Biochem Behav. 1993:46:365-371.
29. Pucilowski 0, Rezvani AH, Janowsky DS. Suppression of alcohol and saccharin preference in rats by a novel Ca channel inhibitor, Goe 5438. Psychopharmacology (Berl). 1992;107:447-452.
30. SO.Gardell LR, Whalen CA, Chattophadyay S, Cavallaro ÇA, Hubbell CL, Reid LD. Combination of naltrexone and fluoxetine on rats' propensity to take alcoholic beverage. Alcohol Clin Exp Res. 1997;21:1435-1439.
31. Zink RW, Rohrbach K, Froehlich JC. Naltrexone and fluoxetine act synergistically to decrease alcohol intake. Alcohol Clin Exp Res. 1997;21(suppl):104A.
32. Rezvani AH, Overstreet DH, Mason GA. Combination pharmacotherapy: a new concept for the treatment of alcoholism. Alcohol Clin Exp Res. 1998;22(suppl):142A.
33. Mason GA, Rezvani AH, Overstreet DH, Garbutt JC. thyrotropin releasing hormone analog TA-0910 reduces voluntary alcohol intake of P rats subchronically in a limited scheduled access paradigm. Alcohol Clin Exp Res. 1996;20:1000-1003.
34. Rezvani AH, Garbutt JC, Shimoda K, Garges PL, Janowsky DS, Mason GA. Attenuation of alcohol preference in alcohol-preferring rats by a novel TRH analogue, TA-0910. Alcohol Clin Exp Res. 1992;16:326-330.
35. Di Chiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Nail Acad Sci USA. 1988;85:5274-5278.
36. Hodge CA, Haraguchi M, Erickson HL, Samson HH. Ventral tegmental microinjections of quinpirole decrease ethanol and sucrose-reinforced responding. Alcohol Clin Exp Res. 1993;17:370-375.
37. Wise RA, Bozarth MA. Action of drugs of abuse on brain reward systems: an update with specific attention to opiates. Pharmacol Biochem Behav. 1982;17:239-243.
38. Weiss F, Lorang MT, Bloom FE, Koob GF. Oral alcohol self-administration stimulates dopamine release in the rat nucleus accumbens: genetic and motivational determinants. J Phamacol Exp Ther. 1993;267:250-258.
39. Farren CK, Catapano D, O'Malley S. Sertraline with naltrexone vs naltrexone alone in the treatment of alcohol dependence. Alcohol Clin Exp Res. 1997;21(suppl):64A.
40. Anton RF, Moak DH, Latham PK. The obsessive-compulsive drinking scale: a new method of assessing outcome in alcoholism treatment studies. Arch Gen Psychiatry. 1996;53:225231.
41. Beck AT, Ward CH, Mendelson M. An inventory for measuring depression. Arch Gen Psychiatry. 1961;3:461-471.
42. Williams LD, Mason BJ. Combination pharmacotherapy in nalmafene non responders. Alcohol Clin Exp Res. 1997;21(suppl):33A.
43. Besson J, Aeby F, Kasas A, Lehert P, Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol Clin Exp Res. 1998;22:573-579.